Literature DB >> 29581297

Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells.

Suresh Bugide1, Michael R Green2,3, Narendra Wajapeyee4.   

Abstract

Natural killer (NK) cell-mediated tumor cell eradication could inhibit tumor initiation and progression. However, the factors that regulate NK cell-mediated cancer cell eradication remain unclear. We determined that hepatocellular carcinoma (HCC) cells exhibit transcriptional down-regulation of NK group 2D (NKG2D) ligands and are largely resistant to NK cell-mediated eradication. Because the down-regulation of NKG2D ligands occurred at the transcriptional level, we tested 32 chemical inhibitors of epigenetic regulators for their ability to re-express NKG2D ligands and enhance HCC cell eradication by NK cells and found that Enhancer of zeste homolog 2 (EZH2) was a transcriptional repressor of NKG2D ligands. The inhibition of EZH2 by small-molecule inhibitors or genetic means enhanced HCC cell eradication by NK cells in a NKG2D ligand-dependent manner. Collectively, these results demonstrate that EZH2 inhibition enhances HCC eradication by NK cells and that EZH2 functions, in part, as an oncogene by inhibiting immune response.

Entities:  

Keywords:  DNMT3A; EZH2; HCC; NK cell ligands; NK cells

Mesh:

Substances:

Year:  2018        PMID: 29581297      PMCID: PMC5899497          DOI: 10.1073/pnas.1802691115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

Review 1.  Innate immune recognition: mechanisms and pathways.

Authors:  R Medzhitov; C Janeway
Journal:  Immunol Rev       Date:  2000-02       Impact factor: 12.988

2.  Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.

Authors:  Katherine B Chiappinelli; Pamela L Strissel; Alexis Desrichard; Huili Li; Christine Henke; Benjamin Akman; Alexander Hein; Neal S Rote; Leslie M Cope; Alexandra Snyder; Vladimir Makarov; Sadna Budhu; Sadna Buhu; Dennis J Slamon; Jedd D Wolchok; Drew M Pardoll; Matthias W Beckmann; Cynthia A Zahnow; Taha Merghoub; Taha Mergoub; Timothy A Chan; Stephen B Baylin; Reiner Strick
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

Review 3.  NK cells in innate immunity.

Authors:  Jessica A Hamerman; Kouetsu Ogasawara; Lewis L Lanier
Journal:  Curr Opin Immunol       Date:  2005-02       Impact factor: 7.486

4.  Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor.

Authors:  Satoko Tahara-Hanaoka; Kazuko Shibuya; Hirayasu Kai; Akitomo Miyamoto; Yoshihiro Morikawa; Nobuhiro Ohkochi; Shin-ichiro Honda; Akira Shibuya
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

5.  Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence.

Authors:  Hiroteru Kamimura; Satoshi Yamagiwa; Atsunori Tsuchiya; Masaaki Takamura; Yasunobu Matsuda; Shogo Ohkoshi; Makoto Inoue; Toshifumi Wakai; Yoshio Shirai; Minoru Nomoto; Yutaka Aoyagi
Journal:  J Hepatol       Date:  2011-07-12       Impact factor: 25.083

Review 6.  Recognition of tumors by the innate immune system and natural killer cells.

Authors:  Assaf Marcus; Benjamin G Gowen; Thornton W Thompson; Alexandre Iannello; Michele Ardolino; Weiwen Deng; Lin Wang; Nataliya Shifrin; David H Raulet
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

7.  The Polycomb group protein EZH2 directly controls DNA methylation.

Authors:  Emmanuelle Viré; Carmen Brenner; Rachel Deplus; Loïc Blanchon; Mario Fraga; Céline Didelot; Lluis Morey; Aleyde Van Eynde; David Bernard; Jean-Marie Vanderwinden; Mathieu Bollen; Manel Esteller; Luciano Di Croce; Yvan de Launoit; François Fuks
Journal:  Nature       Date:  2005-12-14       Impact factor: 49.962

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  Regulation of DNA methylation dictates Cd4 expression during the development of helper and cytotoxic T cell lineages.

Authors:  MacLean Sellars; Jun R Huh; Kenneth Day; Priya D Issuree; Carolina Galan; Stephane Gobeil; Devin Absher; Michael R Green; Dan R Littman
Journal:  Nat Immunol       Date:  2015-06-01       Impact factor: 25.606

10.  A Novel Method for Assessment of Natural Killer Cell Cytotoxicity Using Image Cytometry.

Authors:  Srinivas S Somanchi; Kelsey J McCulley; Anitha Somanchi; Leo L Chan; Dean A Lee
Journal:  PLoS One       Date:  2015-10-22       Impact factor: 3.240

View more
  46 in total

1.  Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer.

Authors:  Liye Zhou; Tenny Mudianto; Xiaojing Ma; Rachel Riley; Ravindra Uppaluri
Journal:  Clin Cancer Res       Date:  2019-09-27       Impact factor: 12.531

Review 2.  Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells.

Authors:  Suresh Bugide; Radoslav Janostiak; Narendra Wajapeyee
Journal:  Trends Cancer       Date:  2018-07-03

Review 3.  Integration of Epigenetic Mechanisms into Non-Genotoxic Carcinogenicity Hazard Assessment: Focus on DNA Methylation and Histone Modifications.

Authors:  Daniel Desaulniers; Paule Vasseur; Abigail Jacobs; M Cecilia Aguila; Norman Ertych; Miriam N Jacobs
Journal:  Int J Mol Sci       Date:  2021-10-11       Impact factor: 5.923

Review 4.  Transcriptional determinants of cancer immunotherapy response and resistance.

Authors:  Romi Gupta; Amitkumar Mehta; Narendra Wajapeyee
Journal:  Trends Cancer       Date:  2022-02-03

5.  EZH2 inhibition: a promising strategy to prevent cancer immune editing.

Authors:  Ning Kang; Mark Eccleston; Pier-Luc Clermont; Maryam Latarani; David Kingsley Male; Yuzhuo Wang; Francesco Crea
Journal:  Epigenomics       Date:  2020-09-17       Impact factor: 4.778

6.  Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer.

Authors:  Deborah L Burkhart; Katherine L Morel; Kristine M Wadosky; David P Labbé; Phillip M Galbo; Zafardjan Dalimov; Bo Xu; Massimo Loda; Leigh Ellis
Journal:  Cancer Prev Res (Phila)       Date:  2020-09-11

Review 7.  Targeting the epigenetic regulation of antitumour immunity.

Authors:  Simon J Hogg; Paul A Beavis; Mark A Dawson; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2020-09-14       Impact factor: 84.694

8.  A prognostic model based on seven immune-related genes predicts the overall survival of patients with hepatocellular carcinoma.

Authors:  Qian Yan; Wenjiang Zheng; Boqing Wang; Baoqian Ye; Huiyan Luo; Xinqian Yang; Ping Zhang; Xiongwen Wang
Journal:  BioData Min       Date:  2021-05-07       Impact factor: 2.522

9.  EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner.

Authors:  Suresh Bugide; Romi Gupta; Michael R Green; Narendra Wajapeyee
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-27       Impact factor: 11.205

10.  BCL11B regulates MICA/B-mediated immune response by acting as a competitive endogenous RNA.

Authors:  Mengyao Qian; Jingwen Geng; Kaili Luo; Zheng Huang; Qinkai Zhang; Jian-An Zhang; Liying Ji; Jianmin Wu
Journal:  Oncogene       Date:  2019-10-31       Impact factor: 8.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.